Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

By S. Graham, H. Jørgensen, E. Allan, C. Pearson, M. Alcorn, L. Richmond, T. Holyoake. Blood, 2002

1,286 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/a4c90992ee04b18d8730784ef821d1d1b4dd9e3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Brian J. Druker
2. J. Cortes
3. S. Morrison

In Hematology

1. Brian J. Druker
2. J. Cortes
3. M. Greaves
4. S. Morrison

In Rheumatology

1. Brian J. Druker
2. J. Cortes

Citations in the corpus

• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia (2005, neutral): “DH p185 (1-426) p210 (1-902–927) p230 (1–1,176) Y177 Myr GAG BCR F G 1a 1b”
• Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “BCR–ABL is required for the survival of proliferating progenitor cells, but not the quiescent CML stem cell”
• MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. (2004, background): “…the relevant “leukemiaport the existence of a subset of leukemic cells that retain long term self-renewal potential. stem cell” in this disorder (Graham et al., 2002)—indeed, it appears that imatinib therapy as a single agent, though quiteWhat is the nature of the qualitative difference…”